A new paradigm for targeting mutant p53 tumours

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1120293

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Over half of all cancers contain mutations in a gene called TP53, also known as the “guardian of the genome”. Mutation of TP53 provides tumour cells with a growth advantage, and leads to resistance to chemotherapy and poor outcomes for patients. We have identified a potential “Achilles heel” in cancers with TP53 mutations. In this project we will establish a new paradigm for treating tumours with TP53 mutations that will be applicable to a large number of patients across all types of cancer.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $901,656.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer biology | novel therapies | oesophageal cancer | p53 | targeted therapy

Related Links